Upstate Active Clinical Trials
Study Title:
A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily
Compared to its Individual Components in Subjects With Early Parkinson’s Disease and to a Calibration
Arm of Pramipexole ER
What is the purpose of the study?
The purpose of this research study is to:• test the safety and effectiveness of the study drug, P2B001, in treating patients with early Parkinson’s disease
Upstate Institutional Review Board (IRB) Number:
1178214Study/Protocol ID:
P2B001/003Study Phase:
Phase IIIPatient Age Group:
AdultsPrincipal Investigator:
Dragos L MihailaWho can I contact for more information?
Name: Jacob D Pusey
Phone: 315-464-9767
Email: puseyj@upstate.edu